JP2022532423A5 - - Google Patents

Info

Publication number
JP2022532423A5
JP2022532423A5 JP2021568564A JP2021568564A JP2022532423A5 JP 2022532423 A5 JP2022532423 A5 JP 2022532423A5 JP 2021568564 A JP2021568564 A JP 2021568564A JP 2021568564 A JP2021568564 A JP 2021568564A JP 2022532423 A5 JP2022532423 A5 JP 2022532423A5
Authority
JP
Japan
Prior art keywords
prs
gene variants
cad
reference population
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532423A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033315 external-priority patent/WO2020236670A1/en
Publication of JP2022532423A publication Critical patent/JP2022532423A/ja
Publication of JP2022532423A5 publication Critical patent/JP2022532423A5/ja
Priority to JP2025229455A priority Critical patent/JP2026062658A/ja
Pending legal-status Critical Current

Links

JP2021568564A 2019-05-17 2020-05-16 心血管系リスクを減らすためのゲノムに基づく方法 Pending JP2022532423A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025229455A JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849670P 2019-05-17 2019-05-17
US62/849,670 2019-05-17
US201962933181P 2019-11-08 2019-11-08
US62/933,181 2019-11-08
PCT/US2020/033315 WO2020236670A1 (en) 2019-05-17 2020-05-16 Genome-based methods for reducing cardiovascular risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025229455A Division JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Publications (2)

Publication Number Publication Date
JP2022532423A JP2022532423A (ja) 2022-07-14
JP2022532423A5 true JP2022532423A5 (enExample) 2023-05-22

Family

ID=70978651

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568564A Pending JP2022532423A (ja) 2019-05-17 2020-05-16 心血管系リスクを減らすためのゲノムに基づく方法
JP2025229455A Pending JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025229455A Pending JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Country Status (6)

Country Link
US (2) US12264366B2 (enExample)
EP (2) EP3969620B1 (enExample)
JP (2) JP2022532423A (enExample)
CA (1) CA3139943A1 (enExample)
MX (1) MX2021014015A (enExample)
WO (1) WO2020236670A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230057410A (ko) 2020-08-25 2023-04-28 리제너론 파마슈티칼스 인코포레이티드 Pcsk9 및 ldlr 조절인자를 사용한 패혈증 치료
CN119998446A (zh) 2022-06-07 2025-05-13 斯克里贝治疗公司 用于靶向pcsk9的组合物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
JP2010526555A (ja) * 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
US20130244892A1 (en) * 2012-02-12 2013-09-19 Aram S. Adourian Risk Factors and Prediction of Adverse Events
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
IN2015DN01767A (enExample) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US10329620B2 (en) * 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US20190017119A1 (en) * 2017-07-12 2019-01-17 The General Hospital Corporation Genetic Risk Predictor

Similar Documents

Publication Publication Date Title
Gatesy et al. A cladistic analysis of mitochondrial ribosomal DNA from the Bovidae
Alla et al. Differential clinical prognostic classifications in dilated and ischemic adbanced heart failure: The EPICAL study
CN113506594B (zh) 冠心病的多基因遗传风险综合评分的构建方法与装置及应用
Dudoit et al. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments
ES2704682T5 (es) Detección y cuantificación de ADN extracelular del donante en la circulación de receptores de trasplantes de órganos
Comas et al. Geographic variation in human mitochondrial DNA control region sequence: the population history of Turkey and its relationship to the European populations.
Viswanathan et al. Association of cardiomyopathy with MYBPC3 D389V and MYBPC3Δ25bp intronic deletion in South Asian descendants
Pasha et al. Angiotensin converting enzyme insertion allele in relation to high altitude adaptation
JP2022513173A5 (enExample)
WO2022247903A1 (zh) 冠心病多基因遗传风险评分及其构建方法与联合临床风险评估应用
Pourafkari et al. Electrocardiography changes in acute aortic dissection—association with troponin leak, coronary anatomy, and prognosis
Yu et al. Computational estimates of annular diameter reveal genetic determinants of mitral valve function and disease
Phan et al. Shedding of yellow fever virus from an imported case in the Netherlands after travel to Brazil
Ang et al. Phylogenetic relationships of the Orang Asli and Iban of Malaysia based on maternal markers
Hartsfield Jr Personalized orthodontics, the future of genetics in practice
Tadros Sudden cardiac death risk stratification in heritable cardiomyopathies: phenotype-based to genotype-based risk scores
Miz et al. Overview of the phylogenetic relationships of some southern Brazilian species from section Torva and related sections of “spiny Solanum”(Solanum subgenus Leptostemonum, Solanaceae)
CN114015768B (zh) 检测FBN1基因突变位点c.G3901T的试剂在制备诊断马凡综合征试剂盒中的应用
de Vargas The Human Genome Project and its importance in clinical medicine
Niama et al. Genetic variability of human pegivirus type 1 (HPgV-1) among Congolese co-infected with hepatitis C virus in Brazzaville, Congo
Yu et al. Computational estimates of mitral annular diameter in systole and diastole cardiac cycle reveal novel genetic determinants of valve function and disease
Voyta et al. Evolution of the skull in arvicoline cricetids (Rodentia) according to 3D morphometric insights: Part 1. Morphological disparity of the palato-spheno-pterygoid complex
CN113416775A (zh) 一种心血管疾病相关snp位点引物组合物及应用
Schwendt et al. Anatomical evaluation of a novel echocardiography based tricuspid valve classification in 60 hearts from body donors
CN111440862A (zh) 一种评估慢性心力衰竭患者预后的引物组、试剂盒及方法